Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology
Sponsor
Pfizer
Protocol Number
A5481082 POLARIS
To Learn More Call
201-510-0910
Older Breast Cancer Patients: Risk for Cognitive Decline
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown Cognition Study
To Learn More Call
201-510-0910
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane) (JUST IN TIME TRIAL)
Type of Cancer
Breast Oncology
Sponsor
Odonate Therapeutics
Protocol Number
ODO-TE-B301
To Learn More Call
201-510-0910
Endocrine Disruptors, Obesity, and Breast Density Among Perimenopausal Women
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown 2016-0215
To Learn More Call
201-510-0910
Optimizing Personalized Care Using Economic Studies of Genomic Testing
Site
Hackensack
Sponsor
Georgetown
Protocol Number
Georgetown U01 COTA Database
To Learn More Call
201-510-0910
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy
Type of Cancer
Breast Oncology
Site
Hackensack
Sponsor
SWOG
Protocol Number
SWOG S1418
To Learn More Call
201-510-0910
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)
Type of Cancer
Breast Oncology
Site
Sparta
Sponsor
Dompe
Protocol Number
REP0114
To Learn More Call
201-510-0910
A Phase I Study of Sterotactic Body Radiotherapy (SBRT)for the Treatment of Multiple Metastases
Type of Cancer
Breast Oncology
Sponsor
NRG Oncology
Protocol Number
NRG Oncology BR003
To Learn More Call
201-510-0910
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
Type of Cancer
Breast Oncology
Site
Howell, Little Silver
Protocol Number
PUMA NER 1301
To Learn More Call
201-510-0910
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Mutlicenter Non-Interventional Study
Type of Cancer
Breast Oncology